ubmslateCN-logo-ubm

CN Mobile Logo

Search form

Topics:

NOVEMber 2015

Volume 29 • Number 11

featured article Featured Article

Current Standards and Novel Treatment Options for Metastatic Pancreatic Adenocarcinoma

Benjamin A. Weinberg, MD, Cinthya S. Yabar, MD, Jonathan R. Brody, PhD, and Michael J. Pishvaian, MD, PhD

This article reviews the current treatment paradigms for metastatic disease, focusing on ways to ameliorate symptoms and lengthen survival. We then summarize recent advances in our understanding of the molecular and cellular aspects of pancreatic cancer.

Read article

 

Oncology

Reviews and Perspectives for the Practicing Oncologist
Featured Article

Nanoparticle-Delivered Chemotherapy: Old Drugs in New Packages

Michael S. Lee, MD, E. Claire Dees, MD, and Andrew Z. Wang, MD

This article reviews the rationale for nanoparticle formulations of existing or previously investigated cytotoxic drugs, describe currently approved nanoparticle formulations of drugs, and discuss some of the most promising clinical trials currently underway.

 

March 2017 Table of Contents

Volume 31 | Number 3
REVIEW ARTICLES

Optimizing the Benefit of CNS Radiation Therapy in the Pediatric Population—PART 1: Understanding and Managing Acute and Late Toxicities
Lindsay S. Rowe, MD, Andra V. Krauze, MD, Holly Ning, PhD, et al

Optimizing the Benefit of CNS Radiation Therapy in the Pediatric Population—PART 2: Novel Methods of Radiation Delivery
Lindsay S. Rowe, MD, Andra V. Krauze, MD, Holly Ning, PhD, et al

Uterine Sarcomas: The Latest Approaches for These Rare but Potentially Deadly Tumors
Jing-Yi Chern, MD, ScM, Leslie R. Boyd, MD, and Stephanie V. Blank, MD

Therapeutic Implications of Molecular Subtyping for Pancreatic Cancer
Michael J. Pishvaian, MD, PhD, and Jonathan R. Brody, PhD

Nanoparticle-Delivered Chemotherapy: Old Drugs in New Packages
Michael S. Lee, MD, E. Claire Dees, MD, and Andrew Z. Wang, MD

Comorbidity Consult

Pubic Bone Osteomyelitis and Pubosymphyseal Urinary Fistula: A Poorly Recognized Complication in Prostate Cancer Survivors
Ramiro Jose Madden-Fuentes, MD, and Andrew C. Peterson, MD

Point/Counterpoint

Standard vs Investigational Agents as Upfront Treatment for High-Risk AML: ‘7+3’ Still Remains the Best Option for Most Patients
Charles A. Schiffer, MD

Standard vs Investigational Agents as Upfront Treatment for High-Risk AML: Depth of Remission Is Key—and This Requires New Strategies
Andrew M. Brunner, MD, and Wendy Stock, MD

Clinical Quandaries

Seventy-Year-Old Man With Large Bladder Mass: Diagnostic and Clinical Challenges of an Uncommon Neoplasm
Tamara P. Lhungay, Alexandra Colvin, Jason Warncke, MD, et al

Q&A

Maurie Markman on the Groundbreaking TAPUR Trial

Editors-in-Chief

Julie VoseJulie M. Vose, MDUniversity of Nebraska Medical School Omaha, Nebraska
Editor-in-Chief, ONCOLOGY
Nora JanjanNora Janjan, MD, MPSA, MBA Senior Fellow for Healthcare Policy, National Center for Policy Analysis
Editor-in-Chief, ONCOLOGY
William C. Wood, MDWilliam C. Wood, MD Department of Surgery, Emory University School of Medicine, Atlanta, Georgia
Editor-in-Chief, ONCOLOGY
Nancy E. Davidson, MDNancy E. Davidson, MD University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania UPMC CancerCenter, Pittsburgh
Editor-in-Chief, ONCOLOGY

 

By clicking Accept, you agree to become a member of the UBM Medica Community.